CTOs on the Move

Iris Plans

www.irisplans.com

 
Iris Plans provides telehealth Advance Care Planning (ACP) services to health insurers and health care providers, reducing unnecessary care for people with serious medical conditions. ACP lowers the cost of care while improving quality and experience.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Axess Ultrasound

Axess Ultrasound is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

6 Degrees Health

6 Degrees Health is built to bring equity and fairness back into the healthcare reimbursement equation. Our cost containment efforts utilize MediVI technology, which supports our solutions with objective, transparent and defensible data. Solutions include everything from provider market analyses, reasonable value claim reports, claim negotiations, and referenced based repricing. MediVI has proven to be a competitive advantage for our veteran negotiators. This combination of experience and objective benchmarks results in highly effective contracts for transplant and other complex health services.

Alliant Management Services

Alliant Management Services is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Children's Harbor Family Ctr

Children's Harbor Family Ctr is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.